Background:
Bacterial conjunctivitis is a serious ocular infection if left
untreated. It is caused by several species of bacteria like Pseudomonas, Staphylococcus
and Mycobacterium.
Objective:
The present investigation explores the development and characterization of
moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL
100 nanosuspension for ocular drug delivery in order to overcome the problems associated
with conventional dosage forms.
Methods:
The nanosuspension prepared by nanoprecipitation technique showed successful
entrapment of both water-soluble drugs in the polymer matrix indicated by their %
entrapment efficiencies.
Results:
Formulations showed a mean particle size <200 nm with narrow size distribution
and positive surface charge due to the presence of quaternary ammonium groups of
Eudragit RL100. FTIR study revealed compatibility among the components, while a
reduction in the crystallinity of formulation was observed in the PXRD study. The release
of both the drugs was found to be sustained in nanosuspension as compared to commercial
eyedrops. Ex vivo studies showed increased transcorneal permeation of drugs from
nanosuspension, where approximately 2.5-fold and 2-fold increase in the permeation was
observed for moxifloxacin hydrochloride and ketorolac tromethamine, respectively. The
formulation was stable at 4°C and room temperature.
Conclusion:
Due to their sustained release, positive surface charge and higher transcorneal
permeation, this will be a promising ocular drug delivery.
